Goldman Sachs Group Analysts Give Novartis (VTX:NOVN) a CHF 105 Price Target
Goldman Sachs Group set a CHF 105 price objective on Novartis (VTX:NOVN) in a research report sent to investors on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
NOVN has been the subject of several other research reports. JPMorgan Chase & Co. set a CHF 82 target price on Novartis and gave the company a sell rating in a research note on Monday, September 9th. Jefferies Financial Group set a CHF 100 target price on Novartis and gave the company a buy rating in a research note on Friday, August 30th. Credit Suisse Group set a CHF 88 target price on Novartis and gave the company a neutral rating in a research note on Friday, July 19th. Morgan Stanley set a CHF 83 target price on Novartis and gave the company a sell rating in a research note on Thursday, May 30th. Finally, Barclays set a CHF 80 target price on Novartis and gave the company a sell rating in a research note on Thursday, September 5th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of CHF 90.85.
Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Featured Article: How are capital gains distributions different for tax-deferred account?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.